title: Type-specific anti-pneumococcal antibody subclass response to vaccination after splenectomy with special reference to lymphoma patients.
abstract: The IgG and IgA antibody subclass responses to pneumococcal polysaccharide antigens type 6A and 19F were studied after immunization with a 14-valent vaccine (Pneumovax, MSD), in 53 splenectomized patients (11 Hodgkin's disease, 13 nonHodgkin's lymphoma (NHL), 9 immune haemolytic anaemia or idiopathic thrombocytopenia purpura and 20 posttraumatic splenectomized patients) and 18 non-splenectomized controls. The antibodies were mainly restricted to the IgG2 and IgA2 subclasses. NHL patients had lower pre-vaccination values to the studied antigens and lower antibody response to vaccination than the other patient groups in which the antibody responses did not differ from those of controls. 1 vaccinated NHL patient experienced two episodes of pneumococcal septicaemia, both occurring after chemotherapy which abolished the previously normal IgG2 antibody levels to the pneumococcal antigens. It is concluded that the antibody response to 6A and 19F antigens after pneumococcal vaccination is not reduced in splenectomized patients but is impaired in immunodeficiency states associated with B-cell lymphoma and treatment with cytostatic drugs.
authors.affiliation: Department of Medicine, Karolinska Hospital, Stockholm, Sweden.
authors.forename: G
authors.initials: G
authors.lastname: Grimfors
authors.forename: M
authors.initials: M
authors.lastname: Björkholm
authors.forename: L
authors.initials: L
authors.lastname: Hammarström
authors.forename: J
authors.initials: J
authors.lastname: Askergren
authors.forename: C I
authors.initials: CI
authors.lastname: Smith
authors.forename: G
authors.initials: G
authors.lastname: Holm
mesh_terms: D000293:Adolescent; D000328:Adult; D000744:Anemia, Hemolytic, Autoimmune / Q000276:immunology / Q000628:therapy; D000907:Antibodies, Bacterial / Q000032:analysis / Q000276:immunology*; D000918:Antibody Specificity / Q000276:immunology*; D001428:Bacterial Vaccines / Q000009:adverse effects / Q000276:immunology*; D003131:Combined Modality Therapy; D004797:Enzyme-Linked Immunosorbent Assay; D006689:Hodgkin Disease / Q000276:immunology / Q000628:therapy; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis; D007074:Immunoglobulin G / Q000032:analysis; D008223:Lymphoma / Q000276:immunology* / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology / Q000628:therapy; D008875:Middle Aged; D011008:Pneumococcal Infections / Q000517:prevention & control; D011696:Purpura, Thrombocytopenic / Q000276:immunology / Q000628:therapy; D013156:Splenectomy; D013296:Streptococcus pneumoniae / Q000276:immunology*
chemical_list: D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D007070:Immunoglobulin A; D007074:Immunoglobulin G